{
    "2019-03-08": [
        [
            {
                "time": "2018-03-15",
                "original_text": "The Kiplinger Dividend 15 Is On a Roll",
                "features": {
                    "keywords": [
                        "Kiplinger Dividend",
                        "roll"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "Donâ€™t Abandon Gilead Stock After Weak Q4 Results",
                "features": {
                    "keywords": [
                        "Gilead",
                        "weak Q4",
                        "abandon"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-03-05",
                "original_text": "Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs",
                "features": {
                    "keywords": [
                        "FDA",
                        "J&J",
                        "antidepressant",
                        "CHMP",
                        "drugs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-19",
                "original_text": "Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC",
                "features": {
                    "keywords": [
                        "Roche",
                        "Tecentriq",
                        "EC",
                        "NSCLC"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}